Double maintains 1 strategies that include ANAB - AnaptysBio, Inc.
Yahoo
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Yahoo
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticip
Yahoo
Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market rebounded from a turbulent week, fueled by easing fears of a government shutdown and renewed confidence in the U.S. economy. Fresh February data signaled that inflation was cooling in line with the Federal Reserve’s targets, helping to calm concerns about economic strain. Looking at the bigger picture, Wells Fargo’s senior global market strategist Scott Wren sees plenty of
SeekingAlpha
ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.
Yahoo
AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and translational data for rosnilimab in RA in Q2 2025Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulatorAnnounced excl
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PDCO | -23.73% | $2.77B | +17.86% | 2.49% |
SMWB | -18.13% | $681.69M | -5.29% | 0.00% |
SW | -16.04% | $24.56B | +1.82% | 2.42% |
OMCL | -14.90% | $1.66B | +28.62% | 0.00% |
RDDT | -12.22% | $19.81B | +133.03% | 0.00% |
EQC | -11.75% | $170.80M | +24.66% | 0.00% |
JKHY | -11.56% | $13.42B | +8.13% | 1.20% |
EQNR | -11.03% | $73.20B | +1.40% | 5.49% |
MDLZ | -11.02% | $85.54B | -2.71% | 2.67% |
GL | -10.91% | $11.08B | +20.01% | 0.75% |
STG | -10.51% | $28.76M | -44.31% | 0.00% |
WST | -10.40% | $16.01B | -42.79% | 0.38% |
ABBV | -9.94% | $362.98B | +15.71% | 3.07% |
PSQH | -9.78% | $93.55M | -56.05% | 0.00% |
TRVG | -9.70% | $104.93M | +63.70% | 0.00% |
BTI | -9.44% | $88.37B | +33.72% | 7.17% |
FIS | -9.13% | $40.12B | +4.31% | 1.97% |
GRMN | -9.08% | $41.96B | +49.32% | 1.65% |
UL | -8.97% | $150.02B | +22.41% | 2.99% |
UUU | -8.94% | $4.14M | +11.18% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TCTM | 0.02% | $3.92M | -82.22% | 0.00% |
INGR | -0.04% | $8.69B | +18.28% | 2.34% |
ACGL | 0.07% | $36.38B | +10.40% | 0.00% |
SWI | -0.10% | $3.19B | +62.24% | 0.00% |
HSY | -0.11% | $33.21B | -15.87% | 3.33% |
RLI | 0.13% | $7.41B | +12.56% | 1.25% |
FE | -0.13% | $23.40B | +6.40% | 4.13% |
GPRK | -0.13% | $409.81M | -17.76% | 7.80% |
SJM | -0.15% | $12.61B | -0.90% | 3.59% |
V | 0.17% | $676.58B | +25.05% | 0.65% |
NBR | 0.18% | $408.70M | -52.58% | 0.00% |
BDX | -0.19% | $65.01B | -7.05% | 1.80% |
KGC | -0.20% | $15.81B | +100.47% | 0.94% |
CINF | -0.20% | $23.11B | +21.68% | 2.30% |
IX | -0.20% | $22.82B | -0.95% | 10.15% |
GIFI | -0.20% | $109.03M | -12.81% | 0.00% |
WEC | 0.20% | $34.37B | +34.01% | 3.09% |
FANG | 0.22% | $46.74B | -20.11% | 3.56% |
HURN | 0.23% | $2.61B | +53.94% | 0.00% |
HRL | 0.24% | $16.84B | -11.83% | 3.62% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IYK | 0.02% | $1.53B | 0.4% |
CANE | 0.08% | $11.28M | 0.29% |
VRIG | 0.09% | $1.44B | 0.3% |
TBIL | 0.11% | $5.39B | 0.15% |
VTEB | -0.11% | $36.03B | 0.03% |
FXN | -0.11% | $335.48M | 0.62% |
BSMR | 0.15% | $235.44M | 0.18% |
SHV | 0.15% | $20.16B | 0.15% |
AFIF | -0.15% | $135.91M | 1.11% |
LTPZ | 0.22% | $735.87M | 0.2% |
BILZ | -0.31% | $734.41M | 0.14% |
HDV | 0.32% | $11.47B | 0.08% |
RSPG | -0.32% | $516.67M | 0.4% |
MINT | 0.36% | $13.22B | 0.35% |
SMMU | -0.38% | $684.32M | 0.35% |
BUXX | 0.39% | $234.79M | 0.25% |
IBMN | 0.41% | $472.63M | 0.18% |
SUB | 0.43% | $8.76B | 0.07% |
FLTR | 0.49% | $2.41B | 0.14% |
FLBR | 0.53% | $177.83M | 0.19% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ST | 37.43% | $3.68B | -33.05% | 2.26% |
CLRB | 36.44% | $13.92M | -92.41% | 0.00% |
CHEF | 35.97% | $2.28B | +56.91% | 0.00% |
PLRX | 34.59% | $86.34M | -90.23% | 0.00% |
HRMY | 34.52% | $1.87B | +2.62% | 0.00% |
SPRY | 34.43% | $1.28B | +38.83% | 0.00% |
CLDX | 34.26% | $1.15B | -56.93% | 0.00% |
VSH | 34.10% | $2.16B | -28.21% | 2.94% |
AVNS | 33.06% | $667.97M | -26.37% | 0.00% |
OCUL | 32.54% | $1.17B | -13.14% | 0.00% |
BLKB | 32.48% | $3.14B | -10.95% | 0.00% |
APGE | 32.39% | $2.25B | -36.95% | 0.00% |
ENTA | 32.35% | $113.06M | -68.28% | 0.00% |
OPCH | 32.33% | $5.71B | +8.14% | 0.00% |
AEIS | 32.02% | $3.64B | -2.74% | 0.48% |
KODK | 31.95% | $504.56M | +24.21% | 0.00% |
DNLI | 31.75% | $2.00B | -29.07% | 0.00% |
ZYME | 31.36% | $836.16M | +23.78% | 0.00% |
QRVO | 31.29% | $6.78B | -36.78% | 0.00% |
IDYA | 31.00% | $1.43B | -61.21% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 43.00% | $48.38M | 0.69% |
XBI | 40.28% | $4.76B | 0.35% |
PTH | 37.98% | $107.91M | 0.6% |
GNOM | 37.08% | $47.13M | 0.5% |
ARKG | 36.35% | $936.86M | 0.75% |
IWC | 35.11% | $797.08M | 0.6% |
PBE | 34.09% | $224.98M | 0.58% |
IBB | 34.06% | $5.61B | 0.45% |
PINK | 33.37% | $138.92M | 0.5% |
ARKX | 32.26% | $258.10M | 0.75% |
IWO | 32.04% | $10.72B | 0.24% |
XPH | 31.06% | $158.14M | 0.35% |
PSC | 30.42% | $704.38M | 0.38% |
VTWO | 30.00% | $10.92B | 0.07% |
ISCG | 29.83% | $655.02M | 0.06% |
IWM | 29.66% | $62.65B | 0.19% |
ARKQ | 29.60% | $822.91M | 0.75% |
KOMP | 29.19% | $1.95B | 0.2% |
ARKK | 29.07% | $5.03B | 0.75% |
SCHA | 28.89% | $15.94B | 0.04% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -21.43% | $416.76M | 1.43% |
DBE | -16.15% | $55.52M | 0.77% |
PDBC | -16.08% | $4.89B | 0.59% |
TAIL | -16.07% | $87.65M | 0.59% |
VIXY | -15.63% | $195.31M | 0.85% |
DBC | -15.55% | $1.36B | 0.87% |
COM | -14.84% | $242.21M | 0.72% |
DBO | -13.90% | $202.41M | 0.77% |
USL | -13.67% | $47.77M | 0.85% |
GSG | -13.54% | $1.05B | 0.75% |
BNO | -13.44% | $99.25M | 1% |
USO | -13.38% | $972.70M | 0.6% |
COMT | -13.24% | $684.20M | 0.48% |
UGA | -13.23% | $87.23M | 0.97% |
OILK | -12.84% | $67.85M | 0.69% |
FTGC | -12.36% | $2.52B | 1.02% |
CMDY | -12.14% | $313.96M | 0.28% |
USCI | -11.47% | $240.82M | 1.07% |
BCI | -11.19% | $1.45B | 0.26% |
BCD | -9.36% | $250.79M | 0.3% |
Current Value
$17.671 Year Return
Current Value
$17.671 Year Return